Literature DB >> 20176414

Lack of association between 11C-PiB and longitudinal brain atrophy in non-demented older individuals.

Ira Driscoll1, Yun Zhou, Yang An, Jitka Sojkova, Christos Davatzikos, Michael A Kraut, Weiguo Ye, Luigi Ferrucci, Chester A Mathis, William E Klunk, Dean F Wong, Susan M Resnick.   

Abstract

Amyloid-β plaques (Aβ) are a hallmark of Alzheimer's disease (AD), begin deposition decades before the incipient disease, and are thought to be associated with neuronal loss, brain atrophy and cognitive impairment. We examine associations between (11)C-PiB-PET measurement of Aβ burden and brain volume changes in the preceding years in 57 non-demented individuals (age 64-86; M=78.7). Participants were prospectively followed through the Baltimore Longitudinal Study of Aging, with up to 10 consecutive MRI scans (M=8.1) and an (11)C-PiB scan approximately 10 years after the initial MRI. Linear mixed effects models were used to determine whether mean cortical (11)C-PiB distribution volume ratios, estimated by fitting a reference tissue model to the measured time activity curves, were associated with longitudinal regional brain volume changes of the whole brain, ventricular CSF, frontal, temporal, parietal, and occipital white and gray matter, the hippocampus, orbito-frontal cortex, and the precuneus. Despite significant longitudinal declines in the volumes of all investigated regions (p<0.05), no associations were detected between current Aβ burden and regional brain volume decline trajectories in the preceding years, nor did the regional volume trajectories differ between those with highest and lowest Aβ burden. Consistent with a threshold model of disease, our findings suggest that Aβ load does not seem to affect brain volume changes in individuals without dementia. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20176414      PMCID: PMC2908199          DOI: 10.1016/j.neurobiolaging.2009.12.008

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  38 in total

1.  Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease.

Authors:  J L Price; J C Morris
Journal:  Ann Neurol       Date:  1999-03       Impact factor: 10.422

Review 2.  Mild cognitive impairment as a clinical entity and treatment target.

Authors:  Ronald C Petersen; John C Morris
Journal:  Arch Neurol       Date:  2005-07

3.  Neuropathology of preclinical and clinical late-onset Alzheimer's disease.

Authors:  J C Troncoso; A M Cataldo; R A Nixon; J L Barnett; M K Lee; F Checler; D R Fowler; J E Smialek; B Crain; L J Martin; C H Kawas
Journal:  Ann Neurol       Date:  1998-05       Impact factor: 10.422

4.  An image-processing system for qualitative and quantitative volumetric analysis of brain images.

Authors:  A F Goldszal; C Davatzikos; D L Pham; M X Yan; R N Bryan; S M Resnick
Journal:  J Comput Assist Tomogr       Date:  1998 Sep-Oct       Impact factor: 1.826

Review 5.  Evolution of neuronal changes in the course of Alzheimer's disease.

Authors:  H Braak; E Braak
Journal:  J Neural Transm Suppl       Date:  1998

6.  The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects.

Authors:  G Blessed; B E Tomlinson; M Roth
Journal:  Br J Psychiatry       Date:  1968-07       Impact factor: 9.319

7.  The Clinical Dementia Rating (CDR): current version and scoring rules.

Authors:  J C Morris
Journal:  Neurology       Date:  1993-11       Impact factor: 9.910

8.  Adult dementia: history, biopsy, pathology.

Authors:  R M Torack
Journal:  Neurosurgery       Date:  1979-05       Impact factor: 4.654

Review 9.  [Post-mortem diagnosis of Alzheimer's disease].

Authors:  D R Thal; H Braak
Journal:  Pathologe       Date:  2005-05       Impact factor: 1.011

10.  The natural history of Alzheimer disease: a longitudinal presymptomatic and symptomatic study of a familial cohort.

Authors:  Alison K Godbolt; Lisa Cipolotti; Hilary Watt; Nick C Fox; John C Janssen; Martin N Rossor
Journal:  Arch Neurol       Date:  2004-11
View more
  25 in total

1.  Effect of complement CR1 on brain amyloid burden during aging and its modification by APOE genotype.

Authors:  Madhav Thambisetty; Yang An; Michael Nalls; Jitka Sojkova; Shanker Swaminathan; Yun Zhou; Andrew B Singleton; Dean F Wong; Luigi Ferrucci; Andrew J Saykin; Susan M Resnick
Journal:  Biol Psychiatry       Date:  2012-09-27       Impact factor: 13.382

2.  The effect of amyloid pathology and glucose metabolism on cortical volume loss over time in Alzheimer's disease.

Authors:  Sofie M Adriaanse; Koene R A van Dijk; Rik Ossenkoppele; Martin Reuter; Nelleke Tolboom; Marissa D Zwan; Maqsood Yaqub; Ronald Boellaard; Albert D Windhorst; Wiesje M van der Flier; Philip Scheltens; Adriaan A Lammertsma; Frederik Barkhof; Bart N M van Berckel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-03-11       Impact factor: 9.236

3.  CSF biomarker and PIB-PET-derived beta-amyloid signature predicts metabolic, gray matter, and cognitive changes in nondemented subjects.

Authors:  Michael Ewers; Philip Insel; William J Jagust; Leslie Shaw; John Q Trojanowski; Paul Aisen; Ronald C Petersen; Norbert Schuff; Michael W Weiner
Journal:  Cereb Cortex       Date:  2011-10-29       Impact factor: 5.357

4.  Cerebrospinal fluid proteins predict longitudinal hippocampal degeneration in early-stage dementia of the Alzheimer type.

Authors:  Lei Wang; Anne M Fagan; Aarti R Shah; Mirza Faisal Beg; John G Csernansky; John C Morris; David M Holtzman
Journal:  Alzheimer Dis Assoc Disord       Date:  2012 Oct-Dec       Impact factor: 2.703

5.  Florbetapir positron emission tomography and cerebrospinal fluid biomarkers.

Authors:  Ann Hake; Paula T Trzepacz; Shufang Wang; Peng Yu; Michael Case; Helen Hochstetler; Michael M Witte; Elisabeth K Degenhardt; Robert A Dean
Journal:  Alzheimers Dement       Date:  2015-04-24       Impact factor: 21.566

Review 6.  Using Pittsburgh Compound B for in vivo PET imaging of fibrillar amyloid-beta.

Authors:  Ann D Cohen; Gil D Rabinovici; Chester A Mathis; William J Jagust; William E Klunk; Milos D Ikonomovic
Journal:  Adv Pharmacol       Date:  2012

Review 7.  Is amyloid-β harmful to the brain? Insights from human imaging studies.

Authors:  William Jagust
Journal:  Brain       Date:  2015-11-27       Impact factor: 13.501

8.  Role of structural MRI in Alzheimer's disease.

Authors:  Prashanthi Vemuri; Clifford R Jack
Journal:  Alzheimers Res Ther       Date:  2010-08-31       Impact factor: 6.982

9.  Synapse stability in the precuneus early in the progression of Alzheimer's disease.

Authors:  Stephen W Scheff; Douglas A Price; Frederick A Schmitt; Kelly N Roberts; Milos D Ikonomovic; Elliott J Mufson
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

10.  Increased brain amyloid deposition in patients with a lifetime history of major depression: evidenced on 18F-florbetapir (AV-45/Amyvid) positron emission tomography.

Authors:  Kuan-Yi Wu; Ing-Tsung Hsiao; Cheng-Sheng Chen; Chia-Hsiang Chen; Chia-Ju Hsieh; Yau-Yau Wai; Chee-Jen Chang; Hsiao-Jung Tseng; Tzue-Chen Yen; Chia-Yih Liu; Kun-Ju Lin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-04       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.